

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

May 12, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO (Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement of patent grant in Macau for diagnostic agent for retinopathy of prematurity and related conditions by our consolidated subsidiary (Japan Innovative Therapeutics, Inc.)

We are pleased to announce that our consolidated subsidiary, Japan Innovative Therapeutics, Inc. ("JIT"), has been granted a patent in Macau related to a diagnostic agent for retinopathy of prematurity and related conditions.

Patent Title:	Substrate for Measuring Tryptase Activity
Country of Registration:	Macau
Application Number :	J/008815

This patent pertains to diagnosing and testing retinopathy of prematurity and anaphylactic shock. JIT has obtained an exclusive license to this patent from Tokyo University of Agriculture and Technology, a National University Corporation, and Peptide Support Co., Ltd.

Regarding the diagnostic agent for ROP and related conditions, JIT has sublicensed exclusive rights to Splendor Health International Limited (Head Office: Hong Kong) for the People's Republic of China, the Hong Kong Special Administrative Region, and Taiwan. While Macau is not included in the sublicense territory, this patent has already been granted in Japan, China, Hong Kong, and Taiwan. The granting of the patent in Macau further strengthens our Group's intellectual property protection.

This matter will have no impact on the earnings forecast for the fiscal year ending December 2025. However, we believe it will contribute to enhancing our corporate value over the medium to long term through future development and related activities.

End

About Splendor Health International Limited

Splendor Health International Limited is a wholly owned subsidiary of Rosso Investments Limited, a Chinese company (hereinafter the "Rosso Group"). The Rosso Group is a pharmaceutical group with a strong academic presence, focusing on therapeutic areas such as pediatrics and urology. Group companies include Shenzhen Rosso Pharmaceutical, a specialized manufacturer of imported pharmaceuticals.